[Jean]

Hi Debbie,
You are on topic...
I aplogize I made a typo error and meant to type positive, (type way too fast)...haste does make waste.

Anyways, getting back to topic.
My thoughts of late have been on duration of herceptin and subtypes. What trials or studies are being done for the subtypes in regards to length of treatment, do we have any results thus far?

I was hoping that some information or data had been released and one of us had viewed it or had some knowledge in regards to adjuvent herceptin trials and offering details.

Just seems there is nothing reported on trials that would place the data in sub groups...as to length of time,
seems one lump sum of duration is what we now have,
I just thought at this point in time we may be hearing more data about subtypes.

I was also curious to the viabilty (length of time) do you think that the herceptin range would change due to subtypes, ( I know this may seem like a strange question Debbie) but it is something my thoughts had hit on.
As we know herceptin works for some not all, what if anything does subtypes play into that? Or does it equate at all?

Last but not least yes, I did not know what length of duration herceptin remained in our systems for
both the adjuvent setting and those patients who have spread of diesease, only knew that for some continued treatment of herceptin will work to remain NED.


Once again thanks,
Jean